Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
MethylGene is a publicly-traded biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics in cancer and infectious diseases. We intend to exploit our HDAC inhibitor technology in other diseases, such as diabetes, inflammation, fungal infections and neurodegenerative disorders. Two cancer product candidates are currently in clinical trials: MGCD0103, partnered with Pharmion Corporation and Taiho Pharmaceutical Co., Ltd., and MG98, partnered with MGI Pharma, Inc. MethylGene has an exclusive license agreement with Merck & Co. for the development and commercialization of small molecule beta-lactamase inhibitors to overcome antibiotic ( www.methylgene.com )
MethylGene Inc.
7220 Frederick Banting Street
Montreal, Quebec H4S 2A1
Canada
Tel: (514) 337-3333
Fax: (514) 337-0550